Zurcher Kantonalbank (Zurich Cantonalbank) Mirati Therapeutics, Inc. Transaction History

Zurcher Kantonalbank (Zurich Cantonalbank)

$28 Billion
Q1 2024

16 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Jan 30, 2024	SELL	$41.99 - $62.38 $28,847 - $42,855	-687 Reduced 6.05%	10,666 $626,000
Q3 2023 Oct 25, 2023	BUY	$27.8 - $45.35 $124,321 - $202,805	4,472 Added 64.99%	11,353 $494,000
Q2 2023 Aug 07, 2023	BUY	$36.13 - $49.49 $35,443 - $48,549	981 Added 16.63%	6,881 $248,000
Q4 2022 Feb 01, 2023	BUY	$41.27 - $98.62 $42,343 - $101,184	1,026 Added 21.05%	5,900 $267,000
Q1 2022 Apr 21, 2022	SELL	$75.82 - $150.97 $17,438 - $34,723	-230 Reduced 4.51%	4,874 $401,000

Q4 2021 Feb 01, 2022	BUY	$132.01 - $190.29 $158,279 - $228,157	1,199 Added 30.7%	5,104 $749,000
Q3 2021 Nov 15, 2021	BUY	$132.13 - $177.45 $1,189 - $1,597	9 Added 0.23%	3,905 $691,000
Q2 2021 Jul 30, 2021	SELL	$144.0 - $179.73 $30,240 - $37,743	-210 Reduced 5.11%	3,896 $629,000
Q1 2021 May 03, 2021	BUY	$158.92 - $221.61 $90,902 - $126,760	572 Added 16.19%	4,106 $703,000
Q4 2020 Jan 28, 2021	BUY	$162.05 - $240.27 $40,026 - $59,346	247 Added 7.51%	3,534 $776,000
Q2 2020 Jul 28, 2020	BUY	$72.01 - $120.39 $84,395 - $141,097	1,172 Added 55.41%	3,287 $375,000
Q1 2020 May 06, 2020	BUY	$69.78 - $116.21 $12,699 - $21,150	182 Added 9.42%	2,115 $163,000
Q4 2019 Jan 21, 2020	BUY	$70.76 - $128.86 $36,158 - $65,847	511 Added 35.94%	1,933 $249,000
Q2 2019 Jul 30, 2019	BUY	$59.49 - $104.71 $13,980 - $24,606	235 Added 19.8%	1,422 $146,000
Q1 2019 Apr 29, 2019	SELL	$43.65 - $78.95 $21,257 - $38,448	-487 Reduced 29.09%	1,187 $87,000
Q2 2018 Aug 06, 2018	BUY	$26.05 - $52.4 $43,607 - $87,717	1,674 New	1,674 $83,000

Others Institutions Holding MRTX

# of Institutions

Shares Held

3.57M

Call Options Held

Put Options Held

36.6K

View Full List

About Mirati Therapeutics, Inc.

Ticker MRTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 55,609,800
Description
Mirati Therapeutics, Inc., a clinical-stage oncology company, develops product candidates to address the genetic and immunological promoters of cancer in the United States. The company develops MRTX849, a KRAS G12C inhibitor, which is in Phase 1/2 clinical trial for treating non-small cell lung (NSCL), colorectal, pancreatic, and other cancers; ...

More about MRTX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Zurcher Kantonalbank (Zurich Cantonalbank), based on Form 13F filings with the SEC.

News

Stay updated on Zurcher Kantonalbank (Zurich Cantonalbank) with notifications on news.

Account